Credit Suisse Group Raises Ra Pharmctl Inc (RARX) Price Target to $23.00

Ra Pharmctl Inc (NASDAQ:RARX) had its price target hoisted by Credit Suisse Group from $19.00 to $23.00 in a report issued on Friday morning. They currently have an outperform rating on the stock.

Several other analysts have also recently weighed in on RARX. Jefferies Group LLC set a $25.00 price target on Ra Pharmctl and gave the stock a buy rating in a report on Friday, August 25th. Zacks Investment Research upgraded Ra Pharmctl from a sell rating to a hold rating in a report on Tuesday, September 26th. Finally, Royal Bank Of Canada assumed coverage on Ra Pharmctl in a report on Thursday, September 14th. They set an outperform rating and a $21.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Ra Pharmctl currently has an average rating of Buy and an average price target of $24.67.

Ra Pharmctl (NASDAQ:RARX) traded down $0.02 during trading hours on Friday, hitting $14.11. The stock had a trading volume of 115,500 shares, compared to its average volume of 118,758. Ra Pharmctl has a 52 week low of $11.20 and a 52 week high of $27.84.

Ra Pharmctl (NASDAQ:RARX) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.06). research analysts anticipate that Ra Pharmctl will post -2.54 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Credit Suisse Group Raises Ra Pharmctl Inc (RARX) Price Target to $23.00” was first published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/credit-suisse-group-raises-ra-pharmctl-inc-rarx-price-target-to-23-00.html.

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in shares of Ra Pharmctl by 33.7% in the second quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock worth $3,746,000 after acquiring an additional 50,432 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Ra Pharmctl by 70.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after acquiring an additional 9,000 shares during the period. Nationwide Fund Advisors lifted its stake in shares of Ra Pharmctl by 1,078.4% in the second quarter. Nationwide Fund Advisors now owns 32,842 shares of the company’s stock worth $615,000 after acquiring an additional 30,055 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Ra Pharmctl by 57.7% in the second quarter. Bank of New York Mellon Corp now owns 37,932 shares of the company’s stock worth $711,000 after acquiring an additional 13,881 shares during the period. Finally, Alps Advisors Inc. acquired a new position in shares of Ra Pharmctl in the second quarter worth approximately $382,000. 66.74% of the stock is currently owned by institutional investors.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply